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Background: By 2009, there were worrying signs from western Cambodia that parasitological responses to
artesunate-containing treatment regimens for uncomplicated Plasmodium falciparum malaria were slower than
elsewhere which suggested the emergence of artemisinin resistance. Vietnam shares a long land border with
Cambodia with a large number of migrants crossing it on a daily basis. Therefore, there is an urgent need to
investigate whether there is any evidence of a change in the parasitological response to the artemisinin derivatives
in Vietnam.
Methods: From August 2010 to May 2011, a randomized controlled clinical trial in uncomplicated falciparum
malaria was conducted to compare two doses of artesunate (AS) (2mg/kg/day versus 4 mg/kg/day for three days)
followed by dihydroartemisinin-piperaquine (DHA-PPQ) and a control arm of DHA-PPQ. The goal was
characterization of the current efficacy of artesunate in southern Vietnam. The primary endpoint of this study was
the parasite clearance half-life; secondary endpoints included the parasite reduction ratios at 24 and 48 hours and
the parasite clearance time.
Results: 166 patients were recruited into the study. The median parasite clearance half-lives were 3.54 (AS 2mg/kg),
2.72 (AS 4mg/kg), and 2.98 hours (DHA-PPQ) (p=0.19). The median parasite-reduction ratio at 24 hours was 48 in
the AS 2mg/kg group compared with 212 and 113 in the other two groups, respectively (p=0.02). The proportions
of patients with a parasite clearance time of >72 hours for AS 2mg/kg, AS 4mg/kg and DHA-PPQ were 27%, 27%,
and 22%, respectively. Early treatment failure occurred in two (4%) and late clinical failure occurred in one (2%) of
the 55 patients in the AS 2mg/kg group, as compared with none in the other two study arms. The PCR-corrected
adequate clinical and parasitological response (APCR) rates in the three groups were 94%, 100%, and 100% (p=0.04).
Conclusions: This study demonstrated faster P. falciparum parasite clearance in southern Vietnam than in western
Cambodia but slower clearance in comparison with historical data from Vietnam. Further studies to determine
whether this represents the emergence of artemisinin resistance in this area are needed. Currently, the therapeutic
response to DHA-PPQ remains satisfactory in southern Vietnam.
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Malaria remains a public health challenge in Vietnam
despite a substantial reduction in the incidence of dis-
ease over the last 20 years. In 2011 there were 45,588
cases reported to the National Malaria Control
Programme (Annual Report NMCP 2011) and 14 deaths
attributed to malaria. Vietnam was one of the first coun-
tries to deploy artemisinin derivatives in its fight against
malaria over twenty years ago [1]. The Vietnamese
health authority took the decision to deploy these drugs
because of the rising morbidity and mortality from mal-
aria and the high level of drug resistance to chloroquine,
sulphadoxine-pyrimethamine, and mefloquine. Since
2005, Vietnam has used dihydroartemisinin-piperaquine
(DHA-PPQ) as the first-line treatment for falciparum
malaria [2]. By 2009, there were worrying signs from
western Cambodia that parasitological responses to
artesunate-containing treatment regimens for uncompli-
cated falciparum malaria were slower than elsewhere
and that unusually high failure rates with artesunate–
mefloquine had been reported [3-5]; both of these sig-
nals suggested the emergence of artemisinin resistance.
In addition, prolongation of parasite clearance time
(PCT) has been reported on the Thai-Myanmar border
[6] and evidence for artemisinin resistance has recently
been reported from this area [7], indicating that artemi-
sinin resistance may be spreading outside Cambodia.
Vietnam shares a long land border with Cambodia with
a large number of migrants and laborers crossing it on a
daily basis. Therefore, there is an urgent need to investigate
whether there is any evidence of a change in the parasito-
logical response to the artemisinin derivatives in Vietnam.
A randomized controlled trial in uncomplicated falciparum
malaria was conducted, to compare two doses of artesu-
nate (AS) followed by dihydroartemisinin-piperaquine
(DHA-PPQ) with a control arm of DHA-PPQ, to
characterize the current efficacy of artesunate in a mal-
aria endemic area of southern Vietnam along the Cam-
bodian border.
Methods
General consideration and justification of intervention
The primary aim of this study was to find out if there
was prolonged parasite clearance in patients receiving
artesunate mono-therapy in Vietnam. Preliminary results
from routine monitoring of DHA-PPQ effectiveness
performed by the Vietnam Malaria Control Program in
the Phuoc Long area had suggested a high proportion
of positive blood smears on day 3 (18%) (LT Dong,
unpublished data). Thus, there was an urgent need for
such a trial.
WHO recommendations on how to detect resistance
to artemisinins was applied [8]: conducting controlled
research studies with oral artesunate monotherapy andmonitoring the parasite clearance half-life as well as the
proportion of patients who are parasitaemic on day 3
(72 hours) as indicators of delayed parasite clearance. If
this proportion exceeds the “rule-out threshold” of 10%,
further detailed studies (pharmacokinetic and genetic)
are advised to confirm the presence of artemisinin resist-
ance in the area. Failure to clear parasites by day 3 indi-
cates a change in the pattern of parasite susceptibility to
artemisinins and is probably the first stage of artemisinin
resistance, which is thought to be associated with a loss
of activity against the early ring stages [3]. It was not
deemed ethical to treat patients with monotherapy
throughout their treatment course and the chosen treat-
ment schedule was initial artesunate monotherapy to as-
sess early parasite clearance followed by three days of
DHA-PPQ according to national policy in Vietnam. The
current recommended dose of artesunate in Vietnam is
4 mg/kg on day 1 and 2 mg/kg on days 2 and 3. How-
ever, this dose has been criticized as being insufficient to
clear parasites. Therefore, two different artesunate regi-
mens with different daily doses of 2 vs. 4 mg/kg/day
were studied for easier comparison with data from
western Cambodia [3]. We also included DHA-PPQ arm
as a control arm. Higher DHA-PPQ fixed - dose com-
bination than the current regimen was used because this
could give an advantage in parasite clearance. In
addition, a three-tablet regimen (once a day for 3 days)
may be more convenient for patients than the current
regimen (four tablets bid for the 1st day, then two
tablets once per day). Randomizing patients to three dif-
ferent treatments also allowed us to perform formal
comparisons between the three regimens, an important
additional aim of this study.
Study site and participants
The study was conducted during the malaria transmis-
sion season, from August 2010 to May 2011 at Phuoc
Long District Hospital (150 beds), Binh Phuoc Province.
Phuoc Long District, 170 km northeast of Ho Chi Minh
City, is an elevated forested area of Binh Phuoc Province.
Phuoc Long covers 1857 sq km in area, is divided into
21 communes and towns, and is home to a population
of 197,897 including an ethnic minority population of
31,918. Phuoc Long is considered as the epicenter of
malaria of Binh Phuoc province and the southern pro-
vinces of Vietnam. In 2009, there were 251 cases of con-
firmed malaria admitted to this District Hospital,
including 138 cases of Plasmodium falciparum. The
study population consisted of patients with uncompli-
cated P. falciparum malaria as detailed below. All adult
patients (≥15 years old) gave written informed consent
before participation. Parents or guardians gave informed
consent on behalf of children. Children aged 12 years or
older additionally gave assent to participate.
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Consecutive patients attending Phuoc Long District Hos-
pital or a nearby community health station were recruited
into the trial if they fulfilled the following criteria: (a) male
and aged > 10 years or female and aged between >10 and
<12 years old, provided they had not reached menarche;
(b) mono-infection with P. falciparum detected by mi-
croscopy; (c) asexual parasitaemia of 10,000–100,000/μL;
(d) axillary or tympanic temperature ≥ 37.5°C or history of
fever during the previous 24 h; (e) ability to swallow oral
medication; (f) ability and willingness to comply with the
study protocol for the duration of the study and to comply
with the study visit schedule; and (g) informed consent/
assent given as stated above. The WHO instruction to ex-
clude pregnant women in the first three months was ap-
plied because artemisinin is contra-indicated during the
first trimester. As the procedure to identify pregnancy
with a urine test and counseling for female patients who
are in child bearing age were too complicated for this field
trial the decision to not include women who menstruate
or are aged over 12 years was made to guarantee no preg-
nant women in this study. The range of asexual parasit-
aemia from 10,000–100,000/μL was chosen based on
results of the paper by Stepniewska et al. [9] which sug-
gested that the proportion of positive blood smears on day
3 would be a tool for assessing population levels of artemi-
sinin resistance and artemisinin resistance is highly un-
likely if the proportion of patients with a positive smear
on day 3 (72 hours) is <3% among patients with parasite
densities of >10,000 to <100,000 parasites/μL at enrol-
ment. Another reason was to aid comparisons with other
studies in the region. Additionally, according to National
Guidelines in Vietnam high parasitaemia >100,000/μL is
an indicator of potential severe malaria in Vietnam and
should be treated with intravenous therapy.
Exclusion criteria
Patients were excluded if they had one or more of the fol-
lowing conditions (a) presence of general danger signs or
severe falciparum malaria according to the definitions of
WHO 2009; (b) mixed or mono-infection with another
Plasmodium species detected by microscopy; (c) pres-
ence of severe malnutrition (defined as a child whose
growth standard is below −3 z-score, has symmetrical
edema involving at least the feet, or has a mid-upper arm
circumference < 110 mm); (d) presence of febrile condi-
tions due to diseases other than malaria (eg measles,
acute lower respiratory tract infection, severe diarrhea
with dehydration) or other known underlying chronic or
severe diseases (eg cardiac, renal and hepatic diseases,
HIV/AIDS); (e) regular medication, which might inter-
fere with anti-malarial pharmacokinetics; (f ) receipt of
anti-malarial drugs in the previous 48 hours; (g) history
of hypersensitivity reactions or contraindications to anyof the medicine(s) being tested or used as alternative
treatment(s); or (h) previous splenectomy.
Intervention
This study was an open-labelled, randomized con-
trolled trial of the efficacy of artesunate (AS) and
dihydroartemisinin-piperaquine (DHA-PPQ) in acute
uncomplicated falciparum malaria with three arms: (i)
AS 2mg/kg/day for three days, (ii) AS 4mg/kg/day for
three days or (iii) DHA-PPQ (DHA 2.4 mg/kg/day +
PPQ 19.2 mg/kg/day) for three days. Following
randomization, the study research doctors were aware
of treatment assignment. However, both the patients
and nonmedical staff (nurses, microscopists, techni-
cians and pharmacists) remained blinded to the treat-
ment allocation. This trial was not primarily designed
to compare the efficacy of study drugs per se but to
determine if there is any evidence of prolonged para-
site clearance following oral AS in falciparum malaria
patients. The two AS arms were followed by a full
course of DHA-PPQ (DHA 1.6 mg/kg/dose + PPQ
12.8 mg/kg/dose), which started on day 4: two doses
on the first day, and a single daily dose on the second
and third days (total three days therapy with DHA-
PPQ) as per Vietnamese national treatment guidelines.
AS was sourced from Guilin Pharmaceutical Com-
pany, PRC, supplied by the WHO and DHA-PPQ was
sourced as ArtecanW, OPC from Vietnam distributed by
the National Malaria Control Programme of Vietnam.
All doses of medicine were administered and recorded
under the supervision of qualified members of the staff
designated by the principal investigator.
Randomization
Block randomization with an allocation ratio of 1:1:1
and variable block lengths of six and nine were used to
make the prediction of the randomized treatment as-
signment of patients impossible. The random allocations
were placed in sealed opaque envelopes, which were
kept in a locked drawer and opened by the research
pharmacists once each patient was enrolled into the trial
after satisfying the inclusion/exclusion criteria. Patients
were enrolled in the order they presented and the sealed
envelopes were opened in strict numerical sequence. In
addition to the treatment arm assignment, patients were
randomly allocated to one of two blood-sampling
schemes for population pharmacokinetic analysis.
Clinical and laboratory procedures
On admission patients were weighed, examined fully,
and had baseline blood samples taken for full blood
count and basic biochemistry. Blood was obtained by a
finger-prick for haematocrit measurements and blood
smears every six hours until two consecutive smears were
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thin blood films were examined on days 2, 3, 7, 14, 21,
28, 35 and 42 and on any other day if the patient
returned spontaneously. The parasitaemia was deter-
mined from the number of parasitized red cells per 1,000
red cells (thin film) or the number of parasites per 400
white blood cells (WBC) (thick film). For each patient,
all blood smears at baseline (100%), all negative
smears (100%), approximately 10% of positive smears
(randomly selected), and approximately 70% of smears
with one parasite per 400WBC were read twice by two
independent qualified microscopists. Parasite densities
were calculated by taking the arithmetic mean of the two
counts as recommended by WHO [10]. Blood smears
with discordant microscopist results (differences in
species diagnosis, discrepancies in the parasite density of
> 50%, or disagreement on presence/absence of parasites)
were re-examined by a third independent microscopist,
and parasite densities were calculated by averaging the
two closest counts. The study patients were observed for
30 min after drug administration for adverse reactions or
vomiting. Any patient who vomited during this observa-
tion period was re-treated with the same dose of medi-
cine and observed for an additional 30 min. If the patient
vomited again, he or she was withdrawn and offered res-
cue therapy. Patients in all three arms were monitored
for 42 days. The follow-up consisted of a fixed schedule
of check-up visits on day 7, 14, 21, 28, 35 and 42 and
corresponding clinical and laboratory examinations.
Polymerase Chain Reaction (PCR) analysis was used to
distinguish between true recrudescence due to treatment
failure and re-infection. Genotyping was done with sam-
ples of all recurrent parasitaemia cases. Parasite DNA was
extracted from dried blood spot samples by the Chelex ex-
traction method [11]. Nested PCR was processed using
specific primers for the three most common molecular
markers msp1, msp2 and glurp [12]. The results were ana-
lysed based on WHO definitions of recrudescence and
new infection [13]. The study protocol, informed consent
documents, relevant supporting information, and all types
of patient recruitment or advertisement information were
submitted to the Ethical Committee of the Vietnam In-
stitute of Malariology, Parasitology and Entomology, the
Oxford University Tropical Research Ethics Committee
and the WHO Research Ethics Review Committee. The
trial was registered at ClinicalTrials.gov (NCT01165372)
[14].
Outcome measures
The primary endpoints of this study was the parasite
clearance rate constant K, i.e. the slope of the log para-
sitaemia–time linear relationship. An equivalent and
more easily interpretable measure, the parasite clearance
half-life T1/2 was also reported. T1/2 can be expressed asT1/2 = 0.693/K. The statistical models used to estimate
the parasite clearance rate constant based on longitu-
dinal parasite counts were fitted using the Parasite
Clearance Estimator developed by the World-Wide
Antimalarial Resistance Network (WWARN) [15]. Sec-
ondary endpoints included (i) PCR-uncorrected and cor-
rected parasitological efficacy of the three treatment
arms over 72 hours and during the follow-up period of
42 days according to WHO guidelines [10] classifying
patients as early treatment failures, late clinical failures,
late parasitological failures, or adequate clinical and
parasitological responses (ACPR); (ii) Parasite clearance
time (PCT100), defined as the time in hours from the
first treatment dose to the first of two consecutive para-
sitaemia counts of zero (patients without documented
parasitaemia clearance were censored at the time of the
last measured positive parasite count); (iii) the propor-
tion of patients with a parasite clearance time >72 hours
after starting each treatment; (iv) parasite-reduction
ratios at 24 and 48 hours, defined as the baseline
parasitaemia value divided by the value at 24 or 48
hours, respectively; (v) fever clearance time, defined as
the time in hours from the first treatment dose to the
start of the first sustained period of 24 hours without
fever (ie temperature<37.5°C);and (vi) adverse and serious
adverse events.
Sample size calculation
Parasite clearance half-lives calculated for 196 Vietnamese
malaria patients enrolled in a clinical trial between
1996–2003 [16] had an approximate log-normal distri-
bution with a median of 3.55 hours and a coefficient of
variation of 0.55. Based on these assumptions, 50
patients in each treatment group provide 80% power (i)
to detect a 0.75-fold difference in geometric mean half-
lives between any two treatment groups (a 75% pro-
longation of parasite clearance half-life is what has been
observed in the emergence of artemisinin resistance),
and (ii) to show that the half-life in any treatment group
is significantly different from 3.55 hours should the true
slope in that group be 4.37 hours or larger. In order to
accommodate a maximum loss-to-follow-up rate of
10%, the sample size was set to 165 patients to meet the
total desired set of final endpoints from 150 patients.
Statistical analysis
Continuous parasitological response measures were sum-
marized as median (inter-quartile range) (IQR) and com-
pared between the groups with the Kruskal-Wallis test.
Parasite and fever clearance time were summarized with
Kaplan-Meier estimates of median and inter-quartile
range, and comparisons between groups were based on
the log-rank test. If the overall comparison between
groups was significant, pair-wise group comparisons were
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the risk of treatment failure was calculated based on the
Kaplan-Meier method including all randomized patients
and, additionally, as a proportion for the subset of patients
reaching documented failure or APCR. Comparisons be-
tween the groups were based on the log-rank test or Fish-
er’s exact test, respectively. All endpoints were reported
and compared both on the intention-to-treat (ITT) popu-
lation containing all randomized patients and the per
protocol population which excluded all patients who were
withdrawn or lost to follow-up during the first three days
of therapy. All analyses were performed with the statistical
software R2.14.1 (R Foundation for Statistical Computing,
Vienna, Austria) and the companion R package mculst 4.0
[17] (for exploratory normal mixture modeling of log-
transformed parasite clearance half lives).
Results
The screening and recruitment of malaria patients are
described in Figure 1. The proportion of patients with
positive smears amongst those presenting to the health
station was 514/6,903 (7%). Most patients recruited into
the study (155/166 = 93%) were adults. On admission
153/166 (92%) patients were febrile and the others had
symptoms of headache or fatigue with a history of fever.
One patient in each treatment group refused to take
anti-malarial drugs. One patient had Plasmodium vivax
on their day two blood smear (AS 2mg/kg), one was
splenectomized (AS 4mg/kg), and one was treated with
IV artesunate (AS 2mg/kg, see adverse events below); all
six were excluded from the per-protocol population.
There were three, eight and two additional patients in
the AS 2mg/kg, AS 4 mg/kg and DHA-PPQ arms, re-
spectively, who withdrew from the study, were lost to
follow-up, or had P. vivax on their blood smear afterFigure 1 Study flow diagram.completion of therapy but before day 42. Therefore, 49,
46 and 52 patients in the three treatment groups com-
pleted the study follow-up schedule. The characteristics
of the three treatment groups at study enrollment were
similar (Table 1).Parasitaemia-related endpoints and fever clearance time
Endpoints are summarized in Table 2 (ITT population)
and Additional file 1: Table S1 (per protocol population).
Parasite clearance rate half-lives and parasite clearance
times (PCT100) were similar across treatment groups
(Figures 2 and 3). Notably, more than 20% of patients
had a PCT100>72 hours in all three groups.
The Spearman rank correlation between initial para-
site densities and PCT100 was 0.23 (p=0.003; cor=0.22
(AS 2mg/kg), 0.28 (AS 4mg/kg), and 0.22 (DHA-PPQ)).
No significant rank correlation was observed between
the initial parasite densities and parasite clearance half-
lives (cor=0.03, p=0.67).
In the PCR-corrected analysis, no treatment failures
were observed in the AS 4mg/kg and the DHA-PPQ
groups compared to three (6%) treatment failures for
patients receiving AS 2mg/kg (p=0.04 for the overall com-
parison among all three treatment groups). Similarly,
parasite reduction ratios at 24 hours were significantly
lower for patients receiving AS 2mg/kg (p=0.02). Eighteen
out of 166 (11%) patients had detectable gametocytaemia
at some time during the study period: on admission five
(9%), six (11%) and four (7%) patients receiving AS 2mg/kg,
AS 4mg/kg and DHA-PPQ, respectively, as well as two
patients, one of each AS group (day 1) and one patient in
the DHA-PPQ group (day 7). Gametocyte clearance times
varied from six hours to 42 days. Fever clearance times
were similar in all three groups (p=0.86).
Table 1 Baseline characteristics by treatment group
Characteristics Artesunate 2mg/kg Artesunate 4mg/kg DHA-Piperaquine
n (N=55) n (N=56) n (N=55)
Age (years) 55 25 (20,38) 56 27 (21,35) 55 27 (21,33)
Children (< 15 years old) 55 4 (7%) 56 4 (7%) 55 3 (5%)
Sex 55 56 55
Female 2 (4%) 2 (4%) 2 (4%)
Male 53 (96%) 54 (96%) 53 (96%)
Ethnicity 55 56 55
- Kinh (Vietnamese) 26 (47%) 21 (38%) 19 (35%)
- S’tieng 25 (45%) 25 (45%) 26 (47%)
- Other ethnicities 4 (7%) 10 (18%) 10 (18%)
Previous malaria episodes 55 24 (44%) 55 25 (45%) 55 26 (47%)
Febrile on admission 55 55 (100%) 56 51 (91%) 55 47 (85%)
Temperature ( °C) 52 39.3(38.5,40.0) 56 38.6 (38.0,39.7) 55 39.0(37.9,39.5)
Height (cm) 55 164(160,169) 56 161(158,167) 55 163(158,167)
Weight (kg) 55 55(49,60) 56 53(50,58) 55 54(48,59)
Parasitaemia (parasites/μL) 55 27129 (12282,50868) 56 29192(19415,55892) 55 29390(16620,55578)
Hematocrit (%) 54 39.4(36.2,43.7) 55 40.0(37.4,42.9) 54 41.6(37.9,44.9)
Hemoglobin (g/dL) 53 13.8(12.6,15.4) 53 14.3(13.3,15.8) 51 14.2(12.9,16.0)
White Blood Cell (x 109/L) 53 5.9(4.6,7.7) 54 5.6(4.4,7.2) 53 6.3(5.1,8.3)
Neutrophils (%) 50 78.7(66.5,82.9) 50 77.2(67.6,83.4) 48 74.9(67.2,80.6)
Lymphocytes (%) 54 15.8(11.7,26.6) 55 15.4(11.3,26.5) 54 19.1(13.6,24.6)
Platelets (x 109/L) 50 93(69,140) 49 119(79,139) 49 111(70,154)
BUN (mmol/L) 52 17.1(14.5,18.2) 55 16.4(14.6,18.4) 54 16.6(14.3,19.1)
Serum creatinine (μmol/L) 53 79.6(61.9,88.4) 55 79.6(70.7,88.4) 54 79.6(70.7,88.4)
Total Bilirubin (μmol/L) 52 18.0(15.4,23.9) 50 20.5(13.4,27.0) 54 20.5(15.4,28.6)
Blood glucose (mmol/L) 52 4.9(4.3,6.4) 55 5.2(4.7,6.4) 54 5.2(4.4,6.1)
AST (IU/L) 53 35(27,49) 55 40(27,50) 54 40(30,58)
ALT (IU/L) 53 37(29,54) 55 39(29,64) 54 42(30,65)
Summary statistic is absolute count (%) for categorical variables and median (IQR) for continuous data.
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pear to be bimodal for all three arms. Indeed, explora-
tory log-normal mixture modeling of all parasite
clearance half lives indicated that the best fitting model
to explain their distribution is a mixture of two log-
normal distributions. Specifically, this model suggests
two underlying populations contributing 58% and 42%
to the total population, and having geometric mean half-
lives of 2.24 and 6.44 hours, respectively, and a common
coefficient of variation of 0.32. Of note, this mixture
model fitted the data much better than a single log-
normal distribution with an improvement in the BIC
(Bayesian information criterion) of 20.43. If real, a bi-
modal distribution of parasite clearance times would
suggest that certain parasite sub-populations may be
associated with longer or shorter clearance phenotypes.
This would be consistent with the results of recentstudies in Asia, [7] [18] [19] all of which show a strong
genetic association with the clearance phenotype.
Adverse and serious adverse events
There were 39 adverse events recorded: 14 (25%) in the
AS 2mg/kg group, 12 (21%) in the AS 4mg/kg group
and 13 (24%) in the DHA-PPQ group. Thirty-three of
these events were low WBC counts (<5000. 109 / L). All
patients recovered uneventfully after two weeks. Only
two serious adverse events were reported: one male pa-
tient in the AS 4mg/kg group was admitted to the hos-
pital on day 21 because of dengue fever. The second
case (AS 2mg/kg) was a 24- year old male patient with a
parasitaemia of 90,800/ L at enrolment; six hours later
the GCS dropped to 14/15 and parasitaemia increased
to 116,008/ L. This patient was treated with IV artesu-
nate because of deterioration of consciousness and was
Table 2 Summary of primary and secondary endpoints by treatment group (ITT population)
Characteristic Artesunate 2mg/kg Artesunate 4mg/kg DHA-Piperaquine Overall comparisons
(N=55) (N=56) (N=55) (p-value )
Clearance rate constant (“slope”) K
[ − loge parasitaemia/hour] $
- median (IQR) 0.20(0.12,0.27) 0.25(0.11,0.39) 0.23(0.12,0.33) 0.19
Clearance half life T1/2 [hours]
- median (IQR) 3.54(2.61,5.88) 2.72(1.80,6.31) 2.98(2.10,5.82) 0.19
- geometric mean (95%CI) 3.85(3.32,4.46) 3.32(2.67,3.89) 3.38(2.89,3.95)
-T1/2 > 6.2hours 11/55(20%) 15/55(27%) 10/55(18%)
Treatment outcomes – WHO
[PCR-uncorrected]
- Early treatment failure (ETF) 2 (4%) 0 (0%) 0 (0%)
- Late clinical failure (LTF) 1(2%) * 0 (0%) 0 (0%)
- Late parasitological failure 0 (0%) 0 (0%) 1 (2%)£
- Withdrawn or lost from follow-up 6 (11%) 10 (18%) 3 (5%)
- Adequate clinical and parasitological
response (ACPR)
46 (84%) 46 (82%) 51 (93%)
Risk of failure [PCR-uncorrected]
- Kaplan-Meier analysis (ITT) # 6% 0% 2% 0.16
- Proportion (“per protocol”) 3/49 (6%) 0/46 (0%) 1/52 (2%) 0.21
Risk of failure [PCR-corrected]
- Kaplan-Meier analysis (ITT) # 6% 0% 0% 0.04¥
- Proportion (“per protocol”) 3/49 (6%) 0/46 (0%) 0/51 (0%) 0.07
Parasite clearance time (PCT100)
- median (IQR) [hours] # 60 (36, 78) 42 (30, 78) 48 (36, 72) 0.49
- Proportion with PCT>72h # 0.27 0.27 0.22 -
Parasite-reduction ratio (%) £
- at 24 hours – median (IQR) 48 (5,282) 212 (11,2931) 113 (12,561) 0.02 €
- at 48 hours – median (IQR) 3430 (151,Inf) Inf (217,Inf) Inf (435,Inf) -
Fever clearance time #
- median (IQR) [hours] 30 (18, 42) 24 (12,42) 24 (18,36) 0.86
Summary measures in each group are median (IQR) or n (%).
($) Slope could not be estimated for one patient on Artesunate 4mg/kg, (*) PCR: recrudescence, (£) PCR: new infection, (#) Kaplan-Meier estimates, (£) Missing
follow-up parasitaemia values at 24 and 48 hours replaced by 0 if the patient had prior documented parasite clearance; no missing data remained after this
imputation. Values of infinity (Inf) correspond to patients without parasitaemia at 24 or 48 hours, respectively.
¥ Pairwise comparisons: Artesunate 2mg/kg vs. Artesunate 4mg/kg (p=0.08), Artesunate 2mg/kg vs. DHA-Piperaquine (p=0.07).
€ Pairwise comparisons: Artesunate 2mg/kg vs. Artesunate 4mg/kg (p=0.01), Artesunate 2mg/kg vs. DHA-Piperaquine (p=0.048), Artesunate 4mg/kg vs DHA-
Piperaquine (p=0.27).
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http://www.malariajournal.com/content/11/1/355then given DHA-PPQ for 3 days as recommended by
the Vietnam Malaria Control Program. His complete
(100%) parasite clearance time was 60 hours but for
determination of the treatment outcome (WHO defin-
ition), he was treated as withdrawn which was agreed to
after reporting to the sponsor of the trial – the WHO.
The patient made a full recovery, was discharged on day
6, and followed up until day 42 for safety reason.
There were two early treatment failures (both on AS
2m/kg). Both patients had positive smears on day 3
(+72hours) and were still febrile. At the end of theirtreatment course one patient had completely recovered
and the other presented with a late parasitological failure
at day 28 due to recrudescence.
Discussion
This study was designed to identify cases of artemisinin-
resistant P. falciparum malaria in southern Vietnam
because of the increasing concern that artemisinin resist-
ance has spread beyond western Cambodia [20]. To assess
the real efficacy of artesunate – separate from the effects
of its partner drug in artemisinin combination therapy
Figure 2 Histograms of parasite clearance half-lives by treatment group.
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http://www.malariajournal.com/content/11/1/355(ACT) – the investigational treatments in this trial during
the first three days were either 2 mg/kg/day or 4 mg/kg/
day of artesunate alone, followed by a full dose of DHA-
PPQ started on day 4 to guarantee the best anti-malarial
treatment for patients and to comply with the recommen-
dations of the National Malaria Control Programme of
Vietnam. Artemisinin resistance is typically identified by
prolongation in parasite clearance times [4] but in field
studies, parasitaemia measures are often only performed
once a day, typically on admission and on days 2 and/or 3
and day 7, in order to assess in vivo susceptibility of anti-
malarial drugs. Once-daily parasitaemia measurements do
not allow an accurate assessment of the parasite clearance
times. To provide an accurate characterization, blood
smears were taken every six hours in our study until two
successive negative smears were observed. The median
parasite clearance time was 60 hours (IQR: 36–78) for theFigure 3 Parasite clearance curves for all 166 patients in the study. M
baseline parasitemia at 72 hours are shown in blue.AS 2mg/kg initial artesunate regimen, 42 hours (IQR: 30–
78) for the 4 mg/kg regimen, and 48 hours (IQR: 36–72)
for DHA-PPQ (P = 0.29). This is comparable with the
results of the 2009 study from Wang Pha, western Thai-
land, where median parasite clearance times of 54 and 48
hours were reported but is considerably shorter than
results from Pailin, Cambodia, where the median parasite
clearance time was 84 hours (IQR: 54–96) for the 2 mg/kg
dose and 72 hours (IQR: 60–96) for the 4 mg/kg dose [3].
An alternative measurement that has been used to as-
sess parasite clearance is the parasite reduction ratio
(PRR). For this study, these measures indicate that after
24 hours 97.93% (AS 2mg/kg), 99.51% (AS 4mg/kg), and
99.12% (DHA-PPQ) of parasites have been cleared from
the blood. This corresponds to a 102-fold reduction after
24 hours and a >104-fold reduction after 48 hours
(Table 2). These PRRs are comparable to those observededian clearance times are shown in red. Patients who had >0.01%
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http://www.malariajournal.com/content/11/1/355in Wang Pha Western, Thailand, and suggest faster
clearance of parasites by approximately one order of
magnitude than those reported from Pailin, Cambodia
[3].
Recently, the slope of the log parasitaemia decline over
time (or equivalently, the parasite clearance half-life) has
been proposed as the most sensitive and robust measure
for studying the anti-malarial effect of drugs [15] and
therefore this was the designated primary endpoint of
this study. Median parasite clearance half-lives in the
three study groups were 3.54, 2.74, and 2.98 hours and
there was no significant difference between the groups.
Comparing these results to those from Dondorp et al.
[3], median half-lives from the present study are again
comparable to those observed in Wang Pha, western
Thailand (3.0 and 2.7 hours) and much lower than those
observed in Pailin (5.0 and 6.0 hours) in 2009.
Because parasite clearance after artemisinin treatment
is rapid, most patients are expected to have cleared their
peripheral parasitaemia by day 3 (72 hours) after the
start of treatment. Thus, the proportion of positive blood
smears on day 3 has been suggested as a tool for asses-
sing population levels of artemisinin resistance. Data
from more than 19,000 cases of acute P. falciparum mal-
aria suggest that artemisinin resistance is highly unlikely
if the proportion of patients with a positive smear on
day 3 (72 hours) is <3% among patients with parasite
densities of <100,000 parasites/μL at enrolment [9]. In
this study, the proportion of patients with parasite clear-
ance times >72 hours was >20% in all three study arms
indicating an urgent need for more information.
In addition to the parasitaemia level on admission,
there are other factors that influence parasite clearance
such as age, individual immune status, types of anti-
malarial drugs used (pharmacokinetic and pharmacody-
namic properties), and parasite virulence. Recently, a
study in western Cambodia suggested that some hostTable 3 Parasite clearance time (PCT100) from studies 2000–2
(Hien TT 2004) [23] Artesunate 1 day (4mg/kg)
mefloquine on day 3
(N=70)
Parasite clearance time
- Mean (range) hours 48.2 (40.6-55.9)
(Thanh NV et al. 2010) [24] 1998
(Artemisinin 5 days) (Artemis
N=65 N
Parasite clearance time
- Median (SD) days 1.8 ± 0.9 2.3
Positive parasitaemia
- On day 3 – n (%) 4 (6%) 6
- On day 4 – n (%) 0factors, such as erythrocyte polymorphisms could affect
parasite clearance half-life [21]. As mentioned previously,
blood samples were collected from the patients of this
study but results on host genetics could not be included
in this manuscript. However, a large scale screening for
hemoglobin disorders in southern Vietnam including
Phuoc Long- Binh Phuoc area during 2003–2007 [22]
showed that the gene frequency for haemoglobin E was
3.3% in Kinh and 44% in S’tieng ethnic people, the two
largest communities in the study area. An exploratory
analysis for the present study revealed no apparent or
statistically significant difference between the parasite
clearance half-lives of the two ethnic subgroups (data not
shown).
Historical parasite clearance data from two comparable
studies in southern Vietnam are summarized in Table 3. A
randomized controlled clinical trial conducted between
2001 and 2002 at the Hospital for Tropical Diseases in Ho
Chi Minh City, Vietnam, included patients with similar
inclusions criteria to this study (parasitaemia > 10,000/μL
and < 100,000 /μL) and treated them with artesunate
(4 mg/kg single dose) vs artesunate (4 mg/kg on day 1, 2
mg/kg on days 2 and 3) both combined with mefloquine
15 mg/kg on day 3 vs a single dose of mefloquine 15 mg/
kg. In that study, mean (range) parasite clearance times
were 48.2 (40.6-55.9) hours and 44.5 (37.7-51.4) hours in
the AS 2 mg/kg and AS 4 mg/kg groups, respectively, and
no patients had positive blood smears at 72 hours [23]. A
review of data from studies in Vietnam from 1998–2009
also reported a very low proportion of positive day 3
smears in patients receiving artemisinin (6% and 9%, in
1998 and 2001, respectively) or artesunate (4% and 2% in
2004/2005, 2008/2009, respectively) [24].
Given certain similarities between the epidemiological
situation in southern Vietnam and Wang Pha, Thailand
– namely, similar parasite clearance times and a decade-
long pattern showing an increased proportion of slow009 in Vietnam
+ Artesunate 3 days (4, 2, 2 mg/kg) +




inin 7 days) (Artesunate 7 days) (Artesunate 7 days)
=69 N=82 N=54
± 0.9 2.1 ± 0.7 1.6 ± 0.7
(9%) 3 (4%) 1 (2%)
0 0 0
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clinical phenotype of P. falciparum infections in Vietnam
is performed. As the conclusions of the Thailand study [7]
showed a genetically-attributable resistance phenotype
evolving during this 10-year period, the possibility that ar-
temisinin resistance has either evolved or been imported
into southern Vietnam sometime during the past decade
should be considered. Molecular studies currently being
done will help determine the proportion of the clearance
phenotype that can be explained by genetics, and on-
going clinical studies at multiple sites in Vietnam will
provide data on changes in parasite clearance occurring
between 2010 and 2012.
Efficacy comparisons between treatment groups were
only a secondary aim of this study and it was only pow-
ered to detect large effects (>75% differences in parasite
clearance half lives). Longer clearance half-lives were
observed in the AS 2mg/kg group but the comparison of
the primary endpoint between treatment groups did not
reach statistical significance. However, there was a sig-
nificantly higher risk of treatment failure (after PCR-cor-
rection) and a lower 24-hour parasite reduction ratio in
the AS 2mg/kg group. This could be explained by the
lower parasiticidal effect of the lower dose, possibly
allowing a greater proportion of parasites to become
“dormant” [25].
The impact of this study for malaria control in Vietnam
is that health policy makers must begin considering
whether the first-line drug combination (dihydroartemisi-
nin-piperaquine) is the optimal choice to treat falciparum
malaria in Vietnam. At the Thai-Myanmar border 10–20%
of patients treated with ACT have been found to be para-
sitaemic after a three-day treatment [20] which, when
considered alongside the >20% patients with positive
smears on day 3 in this trial, suggests the geographic ex-
pansion of artemisinin drug resistance. The assessment of
parasite clearance provided by frequent parasite counts in
this study allows for a detailed characterization of thera-
peutic responses and has shown that maximum parasitici-
dal effects are probably not achieved by the 2mg/kg
artesunate dose. However, overall responses to the cur-
rently recommended ACT remain adequate. Clearly, fur-
ther close monitoring is required [20] to assess whether
this represents the emergence of artemisinin resistance.
However, for the present, the malaria control program in
Vietnam still adheres to the dihydroartemisinin -pipera-
quine combination because there is no alternative anti-
malarial drug which is as good, as available, or as
affordable as the current one.
Conclusions
This study demonstrates faster P. falciparum parasite
clearance in southern Vietnam than in western Cambodia
but slower clearance in comparison with historical datafrom Vietnam. Further studies to determine whether this
represents the emergence of artemisinin resistance in this
area are needed. Currently, the therapeutic response to
DHA-PPQ remains satisfactory in southern Vietnam.
Given the importance of current malaria research to
informing global malaria eradication strategies, the re-
sponse to artemisinin should be monitored in other
regions of the world for the potential emergence and
spread of artemisinin resistance, as artemisinin-based
combination therapy is likely to be a key tool in helping to
achieve and sustain malaria case reductions around the
globe [26]. If artemisinin resistance does spread out of this
region, new strategies and new techniques for resistance
management and containment will be required [27] [28]
to maintain the case reductions that have been achieved
over the past 10 years [29,30].Additional file
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